SCP1 a Potential Cancer Target for Immunotherapy

Mon, 02/04/2013 - 12:05

Synaptonemal Complex Protein 1 (SCP1) is a novel tumor antigen that belongs to the growing family of cancer/testis antigens (CTA). SCP-1 is known to be selectively expressed during the meiotic prophase of spermatocytes and is involved in the pairing of homologous chromosomes during meiosis I. Investigation of a broad spectrum of normal and malignant tissues revealed that expression of SCP-1 transcripts and antigen selectively in a variety of neoplastic tissues and tumor cell lines.

ICC/IC analysis of SCP1 in mouse pachytene preparation. ICC/IC analysis of SCP1 in mouse pachytene preparation.

Immunofluorescence with specific antiserum demonstrated a cell cycle independent nuclear expression of SCP-1 protein in cancer cells. SCP-1 differs from other members of CTA by its localization on chromosome 1 and its frequent expression in malignant gliomas, breast, renal cell and ovarian cancers. Protein expression of SCP-1, as detected by immunohistochemistry (IHC), has been investigated previously in pancreatic and hepatocellular carcinoma (1).  The aberrant expression of SCP-1 in tumors might be a contributing factor to their genomic instability and suggests that the functional role of other CTA might also relate to meiosis (2). Detection of SCP-1 in human epithelial ovarian cancer (EOC) samples and by IHC and ELISA using anti-SCP-1 antibodies revealed that 15 % of the primary tumors had elevated levels of SCP-1 (3) suggesting that further evaluation of SCP-1 as a potential target for vaccine therapy is warranted.

  1. PMID: 14991579
  2. PMID: 9560255
  3. PMID: 15487888

Novus Biologicals offers SCP1 reagents for your research needs including:


Blog Topics